152 related articles for article (PubMed ID: 8380285)
1. Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation.
Koberda J; Grimm EA; Moser RP
J Cancer Res Clin Oncol; 1993; 119(3):131-6. PubMed ID: 8380285
[TBL] [Abstract][Full Text] [Related]
2. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody.
Hirte HW; Clark DA; O'Connell G; Rusthoven J; Mazurka J
Cell Immunol; 1992 Jun; 142(1):207-16. PubMed ID: 1534038
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of IFN-gamma, TNF-alpha, and TNF-beta secretion in IL-2-activated T cells: costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules.
Chong AS; Boussy IA; Graf LH; Scuderi P
Cell Immunol; 1992 Oct; 144(1):69-79. PubMed ID: 1356634
[TBL] [Abstract][Full Text] [Related]
4. Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.
Kikuchi T; Watanabe M; Ohno T
Jpn J Cancer Res; 1991 Mar; 82(3):339-45. PubMed ID: 1827092
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
6. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
7. The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine.
Hess AD; Bright EC
Transplantation; 1991 Jun; 51(6):1232-40. PubMed ID: 1646506
[TBL] [Abstract][Full Text] [Related]
8. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
9. Co-stimulation of T cell proliferation by transforming growth factor-beta 1.
Lee HM; Rich S
J Immunol; 1991 Aug; 147(4):1127-33. PubMed ID: 1831218
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of synovial fluid T cell proliferation by anti-CD5 monoclonal antibodies. A potential mechanism for their immunotherapeutic action in vivo.
Verwilghen J; Kingsley GH; Ceuppens JL; Panayi GS
Arthritis Rheum; 1992 Dec; 35(12):1445-51. PubMed ID: 1282008
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta 1 differentially regulates IL-2 expression and [3H]-thymidine incorporation in CD3 epsilon mAb- and CD28 mAb-activated splenocytes and thymocytes.
McKarns SC; Kaminski NE
Immunopharmacology; 2000 Jul; 48(2):101-15. PubMed ID: 10936508
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.
Nishimura T; Nakamura Y; Takeuchi Y; Gao XH; Tokuda Y; Okumura K; Habu S
Jpn J Cancer Res; 1991 Nov; 82(11):1207-10. PubMed ID: 1836455
[TBL] [Abstract][Full Text] [Related]
14. Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.
Nijhuis EW; vd Wiel-van Kemenade E; Figdor CG; van Lier RA
Cancer Immunol Immunother; 1990; 32(4):245-50. PubMed ID: 2175673
[TBL] [Abstract][Full Text] [Related]
15. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
[TBL] [Abstract][Full Text] [Related]
16. Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction.
Hoskin DW; Reynolds T; Blay J
Cancer Immunol Immunother; 1994 Mar; 38(3):201-7. PubMed ID: 8124689
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2-activated murine cell lines with macrophage- and B-lymphoblast-lytic activity.
Suzuki H; Ikemoto M; Yokoyama A; Kamitani T; Yamashita N; Maruyama M; Yano S
Cell Immunol; 1991 Jan; 132(1):127-39. PubMed ID: 1829651
[TBL] [Abstract][Full Text] [Related]
18. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
19. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.
Smyth MJ; Strobl SL; Young HA; Ortaldo JR; Ochoa AC
J Immunol; 1991 May; 146(10):3289-97. PubMed ID: 1827481
[TBL] [Abstract][Full Text] [Related]
20. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
